Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Rhone Ma Holdings Bhd's average EBITDA Per Share Growth Rate was 35.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 2.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 1.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -2.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Rhone Ma Holdings Bhd was 5.90% per year. The lowest was -11.10% per year. And the median was -0.80% per year.
Rhone Ma Holdings Bhd (XKLS:5278) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Rhone Ma Holdings Bhd 5-Year EBITDA Growth Rate Related Terms
XKLS:5278 vs ZTS, UTHR, VTRS: 5-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rhone Ma Holdings Bhd's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhone Ma Holdings Bhd 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhone Ma Holdings Bhd's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Rhone Ma Holdings Bhd's 5-Year EBITDA Growth Rate falls into.
Rhone Ma Holdings Bhd 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 1.90% mean?
Rhone Ma Holdings Bhd (XKLS:5278) has a 5-Year EBITDA Growth Rate of 1.90% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Rhone Ma Holdings Bhd and its competitors.
Is Rhone Ma Holdings Bhd's 5-Year EBITDA Growth Rate too high?
Rhone Ma Holdings Bhd's current 5-Year EBITDA Growth Rate is 1.90%. Overall, Rhone Ma Holdings Bhd has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rhone Ma Holdings Bhd's 5-Year EBITDA Growth Rate compare to ZTS and UTHR?
Rhone Ma Holdings Bhd's 5-Year EBITDA Growth Rate of 1.90% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Rhone Ma Holdings Bhd and its competitors. Rhone Ma Holdings Bhd's current 5-Year EBITDA Growth Rate is 1.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhone Ma Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd (XKLS:5278) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.94, compared to a current price of RM0.67 — trading 28.7% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 1.90%. Rhone Ma Holdings Bhd's overall GF Score™ is 62/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Rhone Ma Holdings Bhd (XKLS:5278), the current 5-Year EBITDA Growth Rate is 1.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhone Ma Holdings Bhd (XKLS:5278) Overvalued in 2026?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd stock appears to be undervalued.
The current stock price of RM0.67 is trading 28.7% below its estimated GF Value™ of RM0.94.
GuruFocus considers Rhone Ma Holdings Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:5278:
5-Year EBITDA Growth Rate: 1.90%
GF Value™: RM0.94 vs. price of RM0.67 (28.7% below fair value)
No single metric tells the full story. See the XKLS:5278 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhone Ma Holdings Bhd, along with its subsidiaries, is mainly involved in the provision of end-to-end animal health solutions. The Group provides veterinary consultation services, diagnostic laboratory analyses, R&D, and is engaged in the manufacturing and distribution of animal health products. Its reportable segments are: Animal health products and equipment, Food ingredients, and Others. The majority of its revenue is generated from the Animal health products and equipment segment, which is engaged in marketing, trading, distribution, and manufacturing of animal health products and equipment, such as pharmaceuticals, vaccines, feed additives, pesticides, and others. Geographically, the Group's operations are predominantly located in Malaysia.
62GF Score
Get the complete analysis for XKLS:5278
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:5278 has been successfully added to your 
